对CMML中基于分子的预后模型进行比较评估
Luis E Aguirre1,2, Najla Al Ali3, Somedeb Ball4
1Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Blood neoplasia
|October 2, 2025
概括
分子国际预测评分系统 (IPSS-M) 准确预测慢性骨髓单细胞白血病 (CMML) 的结果. 该系统与CMML特异性预后评分系统 (CPSS) -Mol一起,为CMML患者提供了更好的风险分层.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性骨髓 mononcytic白血病 (CMML) 需要准确的预后系统风险分层和治疗指导.
- 现有的系统整合了临床,细胞遗传和分子数据,但基于分子的新型模型显示出了希望.
- 分子国际预后评分系统 (IPSS-M) 是针对骨髓质疏松症候群 (MDS) 开发的,其在CMML中的实用性要求进行调查.
研究的目的:
- 评估IPSS-M在CMML患者中的适用性和预后准确性.
- 将IPSS-M与CMML中其他主要的基于分子的预后模型进行全面比较.
- 评估这些模型在接受低甲基化剂治疗的患者中的预测有效性.
主要方法:
- 从340名CMML患者的临床和分子数据的回顾性分析.
- 应用和比较IPSS-M,修订的国际预后评分系统 (IPSS-R),CMML特异性预后评分系统 (CPSS) -Mol,CPSS,梅奥分子和法语群体骨髓位症模型.
- 评估整体存活率 (OS) 和急性髓性白血病 (AML) 的演变.
主要成果:
- IPSS-M将CMML患者分为6个风险类别,其中的OS中位数和4年AML演变率显著不同 (分别P <.001和P =.008).
- 与较旧的模型相比,CPSS-Mol和IPSS-M都表现出优越的OS歧视.
- 在预测白血病演变方面,CPSS-M显示了最高的准确性,而IPSS-M显示了与CPSS-M相似的预后准确性,并且可靠地适用于CMML.
结论:
- IPSS-M是CMML风险分层的一个有效和可靠的工具,其准确性与CPSS-Mol.相当.
- 包括IPSS-M在内的基于分子的预后模型改善了CMML的风险评估.
- 这些模型在接受低甲基化剂治疗的患者中保持了预测有效性,支持它们在临床决策中使用,特别是在社区环境中.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
561
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
561
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577
Multiple Comparison Tests
4.4K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.4K


